#Influenza #vaccine #effectiveness in #adults 65 years and older, #Denmark, 2015/16 – a rapid epidemiological and virological assessment (@eurosurveillanc, abstract)

[Source: Eurosurveillance, full page: (LINK). Abstract, edited.]

Eurosurveillance, Volume 21, Issue 14, 07 April 2016 / Rapid communication

Influenza vaccine effectiveness in adults 65 years and older, Denmark, 2015/16 – a rapid epidemiological and virological assessment

H Emborg 1 , TG Krause 1 , L Nielsen 2 , MK Thomsen 3 , CB Christiansen 4 , MN Skov 5 , XC Nielsen 6 , LS Weinreich 7 , TK Fischer 8 , J Rønn 8 , R Trebbien 8

Author affiliations: 1. Department of Infectious Disease Epidemiology, Statens Serum Institut, Copenhagen, Denmark; 2. Department of Clinical Microbiology, Herlev Hospital, Herlev, Denmark; 3. Department of Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark; 4. Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark; 5. Department of Clinical Microbiology, Odense University Hospital, Odense C, Denmark; 6. Department of Clinical Microbiology, Slagelse Hospital, Slagelse, Denmark; 7. Department of Clinical Microbiology, Aalborg University Hospital, Aalborg, Denmark; 8. Department of Microbiological Diagnostics and Virology, National Influenza Center, Statens Serum Institut, Copenhagen, Denmark

Correspondence: Hanne-Dorthe Emborg (hde@ssi.dk)

Citation style for this article: Emborg H, Krause TG, Nielsen L, Thomsen MK, Christiansen CB, Skov MN, Nielsen XC, Weinreich LS, Fischer TK, Rønn J, Trebbien R. Influenza vaccine effectiveness in adults 65 years and older, Denmark, 2015/16 – a rapid epidemiological and virological assessment. Euro Surveill. 2016;21(14):pii=30189. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2016.21.14.30189

Received:16 March 2016; Accepted:07 April 2016

 

Abstract

In Denmark, both influenza A(H1N1)pdm09 and influenza B co-circulated in the 2015/16 season. We estimated the vaccine effectiveness (VE) of the trivalent influenza vaccine in patients 65 years and older using the test-negative case–control design. The adjusted VE against influenza A(H1N1)pdm09 was 35.0% (95% confidence interval (CI): 11.1–52.4) and against influenza B 4.1% (95% CI: −22.0 to 24.7). The majority of influenza A(H1N1)pdm09 circulating in 2015/16 belonged to the new genetic subgroup subclade 6B.1.

Keywords: Research; Abstracts; Seasonal Influenza; Vaccines; H1N1pdm09; Denmark.

——

Published by

Giuseppe Michieli

I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.